CGN-89564-2 is another name of Flavr Savr TM
tomato, the first genetically modified (GM) crop which was granted a license by
the U.S. Food and Drug Adminstration (FDA) for human consumption in 1992.
Subsequently, there has been a global rapid acceptance of GM crops to fulfil
the ever rising demand for food and fodder. It is very important that the
biotechnology must be developed with appropriate safety measures as it has
great potential to improve human well-being. Taking into account the safety of
biological diversity, Cartagena Protocol on Biosafety was adopted on 29 January
2000 in Montreal, Canada as a supplementary agreement under the United Nations Convention of BiologicalDiversity (UNCBD) and entered into force on 11 September 2003. (There is one more supplementary agreement under
UNCBD that is the Nagoya Protocol on Access andBenefit-Sharing.) It was named in honour
of Cartagena, Colombia, where negotiations were anticipated to accomplish in
February 1999. It is a legally
binding global treaty that commits to ensure the
safe handling, transport and use of living
modified organisms (LMOs) resulting from modern biotechnology that may have
opposing effects on biodiversity, also considering the risks to human health.
Objective
Article 1 of the Cartagena Protocol on
Biosafety, contains the core objective of the
protocol that is to “contribute to ensure an adequate level of protection in
the field of safe transfer, handling and use of the living modified organisms
resulting from modern biotechnology that may have adverse effects on the
conservation and sustainable use of biological
diversity, taking also into account the risks to human health, and
specifically focusing on transboundary movements”
Scope of the
Protocol
The Protocol applies to the “transboundary movement, transit,
handling and use of all living modified organisms that may have adverse effects
on the conservation and sustainable use of biological diversity, taking into
account risks to human health”.
But it does not apply on the products derived from the living
modified organisms and the transboundary movement of LMOs which
are pharmaceuticals for humans that are addressed by other relevant
international agreements or organisations.
Main features of the Protocol
v It
establishes an Advanced Informed
Agreement (AIA) procedure that requires exporters to seek prior approval from
the party of import for the first intentional transboundary movement of LMOs
meant to introduce into their environment.
v An internet-based “Biosafety Clearing-House” is
established to help countries exchange scientific, technical, environmental and
legal information about LMOs and assist parties to implement protocol.
v The
protocol entails that decisions on proposed import should be based on risk
assessment, which must be undertaken in a scientific manner.
v The Protocol promotes international cooperation to help
developing countries acquire resources and capacity to use biotechnology safely
and regulate it proficiently.
v Member governments must obligate themselves to promoting
public awareness, insuring public access to information, and public
consultation.
Conference of
Parties (COP/MOP)
Currently, there are 172 parties to the convention which
meets every two year to discuss the implementation of the protocol’s
provisions. These meetings are called Conference of Parties or Meetings of
Parties (MOP).
Conclusion
The Cartagena Protocol on Biosafety has been proved as an
important step to provide a global regulatory framework that create an enabling
environment for the safe and sound application of biotechnology without having
opposing effects to the environment and to human health.
Thank
you for reading this article, you can share your feedback in the comments
section. You can also suggest the topics on which you want our analysis.
Please
like and subscribe to this post for up-to-dated information on world affairs.
Follow
our facebook page for more such articles at:- https://www.facebook.com/thecivilanalyst
Good
ReplyDelete